Division of Hematology and Oncology

Cathy Eng, MD
October 15, 2024

Cathy Eng named Vanderbilt-Ingram Cancer Center associate director of Strategic Relations and Research Partnerships 

Her new responsibilities will include promoting clinical research by developing new strategic partnerships with pharmaceutical and biotech companies.

color-enhanced cross section of tumor tissue
October 7, 2024

New Video: Study shows cancer vaccine blocks tumor progression at early lesion stage

Senior author Mary Philip, MD, PhD, associate director of the Vanderbilt Institute for Infection, Immunology and Inflammation, talks about her Journal for ImmunoTherapy of Cancer study.
The findings support further vaccine investigation to make long-term, progression-free survival a reality for more cancer patients.

(iStock image)
September 30, 2024

VUMC researchers awarded $1.9 million for AI-driven cancer data extraction

The project seeks to reduce the time for clinical chart abstraction by 90% while maintaining human-level accuracy.

Patient Kathy Wilcox, here with her husband, John, is an avid flyer with an indefatigable zest for life; a quality that has not been shaken by her cancer diagnoses.
September 27, 2024

Vanderbilt-Ingram Cancer Center part of new ‘Rewriting Cancer’ series

Launched Sept. 17-19 during the World Cancer Congress in Geneva, Switzerland, “Rewriting Cancer” aims to enhance understanding and inspire audiences by exploring the most innovative, inclusive and impactful solutions for cancer prevention, diagnosis, treatment and care globally.

July 10, 2024

Clinical trial for rectal cancer subtype shows promise for less aggressive treatment

The findings were so promising that the clinical trial is being redesigned to investigate whether radiation treatment can also be avoided.

June 25, 2024

International trial introduces another curative option for sickle cell disease 

The therapy, haploidentical bone marrow transplant with thiotepa and posttransplant cyclophosphamide, is as safe and more affordable than the recently FDA-approved myeloablative gene therapy and gene editing treatments.